Corrigendum: Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation

Affiliations

• ¹ McMDC, Harrogate, UK.
• ² Warwick Evidence, Division of Health Sciences, University of Warwick, Coventry, UK.
• ³ Berlin, Germany.
• ⁴ Effective Evidence, Waterlooville, UK.
• ⁵ University of Central Lancashire, Preston, UK.
• ⁶ Queen Elizabeth University Hospital, Glasgow, UK.
• ⁷ University of Oxford, Oxford, UK.